Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review

E-ISSN： 1875-5453|16|2|97-104

ISSN： 1389-2002

Source： Current Drug Metabolism, Vol.16, Iss.2, 2015-01, pp. : 97-104

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics of Rosiglitazone in Patients with End-stage Renal Disease

By Thompson-Culkin K Zussman B Miller AK Freed MI

The Journal of International Medical Research, Vol. 30, Iss. 4, 2002-07 ,pp. : 391-399

Field House Publishing

Access to resources Recommend Favorite

Lanthanum Carbonate: A Review of its Use in Lowering Serum Phosphate in Patients with End-Stage Renal Disease

By Curran Monique P. Robinson Dean M.

Drugs, Vol. 69, Iss. 16, 2009-11 ,pp. : 2329-2349

Adis International

Access to resources Recommend Favorite

Sevelamer Hydrochloride: A Review of its Use for Hyperphosphataemia in Patients with End-Stage Renal Disease on Haemodialysis

By Goldsmith David R. Scott Lesley J. Cvetković Risto S. Plosker Greg L.

Drugs, Vol. 68, Iss. 1, 2008-01 ,pp. : 85-104

Adis International

Access to resources Recommend Favorite

Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report

Current Drug Targets, Vol. 17, Iss. 15, 2016-12 ,pp. : 1755-1760

Bentham Science Publishers

Access to resources Recommend Favorite

Aciclovir/gabapentin: Encephalopathy in patients with end-stage renal disease: 2 case reports

Reactions Weekly, Vol. 1, Iss. 1286, 2010-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite